Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.

Publikation

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland.

Wissenschaftlicher Artikel/Review - 13.12.2023

Thoueille Paul, Alves Saldanha Susana, Schaller Fabian, Choong Eva, Munting Aline, Cavassini Matthias, Braun Dominique, Günthard Huldyrich F, Kusejko Katharina, Surial Bernard, Furrer Hansjakob, Rauch Andri, Rougemont Mathieu, Ustero Pilar, Calmy Alexandra, Stoeckle Marcel, Marzolini Catia, Di Benedetto Caroline, Bernasconi Enos, Schmid Patrick, Piso Rein Jan, Andre Pascal, Girardin François R, Guidi Monia, Buclin Thierry, Decosterd Laurent Arthur, Swiss HIV Cohort Study SHCS

Zitation

Thoueille P, Alves Saldanha S, Schaller F, Choong E, Munting A, Cavassini M, Braun D, Günthard H, Kusejko K, Surial B, Furrer H, Rauch A, Rougemont M, Ustero P, Calmy A, Stoeckle M, Marzolini C, Di Benedetto C, Bernasconi E, Schmid P, Piso R, Andre P, Girardin F, Guidi M, Buclin T, Decosterd L, Swiss HIV Cohort Study S. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland. Lancet Reg Health Eur 2023; 36:100793.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lancet Reg Health Eur 2023; 36

Veröffentlichungsdatum

13.12.2023

eISSN (Online)

2666-7762

Seiten

100793

Kurzbeschreibung/Zielsetzung

The efficacy and tolerability of long-acting cabotegravir and rilpivirine were demonstrated in Phase III trials. However, low concentrations combined with other risk factors have been associated with an increased risk of virologic failure. This study aims to verify whether drug concentrations measured in a real-world setting are consistent with those previously reported.